Please use this identifier to cite or link to this item: http://hdl.handle.net/11189/5600
Title: Anti-platelet aggregation of mixtures of betulinic oleanolic and maslinic acids and derivatives from medicinal plants
Authors: Osunsanmi, Foluso O 
Oyinloye, Babatunji E 
Mosa, Rebamang A 
Ikhile, Monisola I 
Ngila, J Catherine 
Shode, Francis O 
Singh, M 
Opoku, Andy R 
Keywords: Platelet aggregation;Agonist;Aspirin;Betulinic Acid;Oleanolic Acid;Maslinic Acid;Cytotoxicity
Issue Date: 2016
Publisher: Tropical Journal of Pharmaceutical Research
Abstract: Purpose: To evaluate the antiplatelet aggregation and cytotoxic potential of betulinic acid (BA), oleanolic acid (OA), maslinic acid (MA) and their derivatives (3-β-acetyloleanolic acid (OAA) and 3-β- acetylbeutulinic (BAA) from medicinal plants. Methods: The compounds were characterized by nuclear magnetic resonance (NMR, both carbon 13 and hydrogen 1) (NMR), infra-red (FTIR) and mass spectroscopy (MS). The platelet aggregation inhibitory activities of the compounds (1, 3, 5 and 10 mg/ml) were investigated separately on adenosine diphosphate (ADP) and thrombin-induced rat platelet aggregation. Cytotoxicity studies were carried out on human embryonic kidney (HEK293) and hepatocellular carcinoma (HEPG2) cell lines using 3, 4, 5- dimethylthiazol-2-yl)-2-5-diphenyltetrazoliumbromide assay. Results: The compounds significantly (p < 0.05) inhibited platelet aggregation in a dose-dependent manner on thrombin and ADP agonist. BAA/OAA showed the highest activity on both agonists with IC50 of 2.86 and 3.05 mg/mL respectively. BAA/OAA also showed better antiplatelet activity than aspirin (IC50 of 6.45 and 7.36 mg/mL, respectively). In addition the compound (BA/OA, BAA/OAA and MA/OA) exhibited low cytotoxic effect on both HEK293 cells (IC50: 724.43, 269.08 and 407.89 mg/mL respectively) and HEPG2 (IC50: 585.38, 499.78 and 499.78 mg/mL, respectively). Conclusion: BAA/OAA demonstrate the best antiplatelet potential and low cytotoxicity of in all the tests, and therefore can serve as safer antiplatelet agents.
URI: http://dx.doi.org/10.4314/tjpr.v15i8.3
http://hdl.handle.net/11189/5600
Appears in Collections:Appsc - Journal Articles (DHET subsidised)

Show full item record

Page view(s)

24
Last Week
0
Last month
0
checked on Feb 9, 2021

Google ScholarTM

Check


This item is licensed under a Creative Commons License Creative Commons